At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02652 CF PHARMTECH
Trading 03-20 13:02:06
24.280
-0.900
-3.57%
High26.200
Low24.040
Vol643.00K
Open25.980
D1 Closing25.180
Amplitude8.58%
Mkt Cap9.98B
Tradable Cap7.33B
Total Shares411.00M
T/O16.02M
T/O Rate0.21%
Tradable Shares302.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CF PHARMTECH (02652) Schedules 30 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal
Major Milestone CF Pharmtech, Inc. 2652.HK Announces Ind Acceptance for Pah New Drug With a Globally Innovative Improved Mechanism, Marking Another Milestone for Its Precision Drug Delivery Platform
CF PharmTech Inc is a China-based company primarily focused on the research & development, manufacturing and commercialization of inhalation technologies and inhalation drugs. The Company’s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Company's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The Company mainly conducts its business in the domestic market.